212 related articles for article (PubMed ID: 15615113)
21. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
22. Targeting sclerostin as potential treatment of osteoporosis.
Papapoulos SE
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i119-22. PubMed ID: 21339215
[TBL] [Abstract][Full Text] [Related]
23. NMR structure of the Wnt modulator protein Sclerostin.
Weidauer SE; Schmieder P; Beerbaum M; Schmitz W; Oschkinat H; Mueller TD
Biochem Biophys Res Commun; 2009 Feb; 380(1):160-5. PubMed ID: 19166819
[TBL] [Abstract][Full Text] [Related]
24. Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
Leupin O; Kramer I; Collette NM; Loots GG; Natt F; Kneissel M; Keller H
J Bone Miner Res; 2007 Dec; 22(12):1957-67. PubMed ID: 17696759
[TBL] [Abstract][Full Text] [Related]
25. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.
Loots GG; Kneissel M; Keller H; Baptist M; Chang J; Collette NM; Ovcharenko D; Plajzer-Frick I; Rubin EM
Genome Res; 2005 Jul; 15(7):928-35. PubMed ID: 15965026
[TBL] [Abstract][Full Text] [Related]
26. A known SOST gene mutation causes sclerosteosis in a familial and an isolated case from Brazilian origin.
Kim CA; Honjo R; Bertola D; Albano L; Oliveira L; Jales S; Siqueira J; Castilho A; Balemans W; Piters E; Jennes K; Van Hul W
Genet Test; 2008 Dec; 12(4):475-9. PubMed ID: 19072561
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes.
Bellido T
J Musculoskelet Neuronal Interact; 2006; 6(4):358-9. PubMed ID: 17185824
[No Abstract] [Full Text] [Related]
28. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).
Balemans W; Ebeling M; Patel N; Van Hul E; Olson P; Dioszegi M; Lacza C; Wuyts W; Van Den Ende J; Willems P; Paes-Alves AF; Hill S; Bueno M; Ramos FJ; Tacconi P; Dikkers FG; Stratakis C; Lindpaintner K; Vickery B; Foernzler D; Van Hul W
Hum Mol Genet; 2001 Mar; 10(5):537-43. PubMed ID: 11181578
[TBL] [Abstract][Full Text] [Related]
29. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.
van Bezooijen RL; Roelen BA; Visser A; van der Wee-Pals L; de Wilt E; Karperien M; Hamersma H; Papapoulos SE; ten Dijke P; Löwik CW
J Exp Med; 2004 Mar; 199(6):805-14. PubMed ID: 15024046
[TBL] [Abstract][Full Text] [Related]
30. Lentivirus-mediated gene transfer induces long-term transgene expression of BMP-2 in vitro and new bone formation in vivo.
Sugiyama O; An DS; Kung SP; Feeley BT; Gamradt S; Liu NQ; Chen IS; Lieberman JR
Mol Ther; 2005 Mar; 11(3):390-8. PubMed ID: 15727935
[TBL] [Abstract][Full Text] [Related]
31. Sclerostin: therapeutic horizons based upon its actions.
Costa AG; Bilezikian JP
Curr Osteoporos Rep; 2012 Mar; 10(1):64-72. PubMed ID: 22234741
[TBL] [Abstract][Full Text] [Related]
32. [Expression and regulation of the SOST gene].
Qin LJ; Ding DX; Cui LL; Huang QY
Yi Chuan; 2013 Aug; 35(8):939-47. PubMed ID: 23956082
[TBL] [Abstract][Full Text] [Related]
33. Sclerosteosis: Report of type 1 or 2 in three Indian Tamil families and literature review.
Whyte MP; Deepak Amalnath S; McAlister WH; Pedapati R; Muthupillai V; Duan S; Huskey M; Bijanki VN; Mumm S
Bone; 2018 Nov; 116():321-332. PubMed ID: 30077757
[TBL] [Abstract][Full Text] [Related]
34. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease.
Balemans W; Patel N; Ebeling M; Van Hul E; Wuyts W; Lacza C; Dioszegi M; Dikkers FG; Hildering P; Willems PJ; Verheij JB; Lindpaintner K; Vickery B; Foernzler D; Van Hul W
J Med Genet; 2002 Feb; 39(2):91-7. PubMed ID: 11836356
[TBL] [Abstract][Full Text] [Related]
35. SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development.
van Bezooijen RL; Deruiter MC; Vilain N; Monteiro RM; Visser A; van der Wee-Pals L; van Munsteren CJ; Hogendoorn PC; Aguet M; Mummery CL; Papapoulos SE; Ten Dijke P; Löwik CW
Dev Dyn; 2007 Feb; 236(2):606-12. PubMed ID: 17195180
[TBL] [Abstract][Full Text] [Related]
36. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone.
Silvestrini G; Ballanti P; Leopizzi M; Sebastiani M; Berni S; Di Vito M; Bonucci E
J Mol Histol; 2007 Aug; 38(4):261-9. PubMed ID: 17549589
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites.
Uitterlinden AG; Arp PP; Paeper BW; Charmley P; Proll S; Rivadeneira F; Fang Y; van Meurs JB; Britschgi TB; Latham JA; Schatzman RC; Pols HA; Brunkow ME
Am J Hum Genet; 2004 Dec; 75(6):1032-45. PubMed ID: 15514891
[TBL] [Abstract][Full Text] [Related]
38. Sclerosteosis caused by a novel nonsense mutation of SOST in a consanguineous family.
He WT; Chen C; Pan C; Zhang MX; Yu XF; Wang DW; Hu SH
Clin Genet; 2016 Feb; 89(2):205-9. PubMed ID: 26283468
[TBL] [Abstract][Full Text] [Related]
39. Paradoxical Sost gene expression response to mechanical unloading in metaphyseal bone.
Macias BR; Aspenberg P; Agholme F
Bone; 2013 Apr; 53(2):515-9. PubMed ID: 23337040
[TBL] [Abstract][Full Text] [Related]
40. A Novel Loss-of-Sclerostin Function Mutation in a First Egyptian Family with Sclerosteosis.
Fayez A; Aglan M; Esmaiel N; El Zanaty T; Abdel Kader M; El Ruby M
Biomed Res Int; 2015; 2015():517815. PubMed ID: 25984533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
